Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Tumour suppression by p53: a role for the DNA damage response?

Meek DW.

Nat Rev Cancer. 2009 Oct;9(10):714-23. doi: 10.1038/nrc2716. Epub 2009 Sep 4. Review.

PMID:
19730431
2.
3.

p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.

Tolbert D, Lu X, Yin C, Tantama M, Van Dyke T.

Mol Cell Biol. 2002 Jan;22(1):370-7.

4.

DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Gjerset RA.

J Mol Histol. 2006 Sep;37(5-7):239-51. Epub 2006 Jul 20. Review.

PMID:
16855788
5.

Tumour biology: Policing of oncogene activity by p53.

Efeyan A, Garcia-Cao I, Herranz D, Velasco-Miguel S, Serrano M.

Nature. 2006 Sep 14;443(7108):159. No abstract available.

PMID:
16971940
6.

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.

Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI.

Nature. 2006 Sep 14;443(7108):214-7. Epub 2006 Sep 6.

PMID:
16957739
7.

ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets.

Carlos AR, Escandell JM, Kotsantis P, Suwaki N, Bouwman P, Badie S, Folio C, Benitez J, Gomez-Lopez G, Pisano DG, Jonkers J, Tarsounas M.

Nat Commun. 2013;4:2697. doi: 10.1038/ncomms3697.

PMID:
24162189
8.
9.

CKIα ablation highlights a critical role for p53 in invasiveness control.

Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, Wiener Z, Alitalo K, Oren M, Pikarsky E, Ben-Neriah Y.

Nature. 2011 Feb 17;470(7334):409-13. doi: 10.1038/nature09673.

PMID:
21331045
10.

Unravelling mechanisms of p53-mediated tumour suppression.

Bieging KT, Mello SS, Attardi LD.

Nat Rev Cancer. 2014 May;14(5):359-70. doi: 10.1038/nrc3711. Epub 2014 Apr 17.

11.
12.

Role for PP2A in ARF signaling to p53.

Moule MG, Collins CH, McCormick F, Fried M.

Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14063-6. Epub 2004 Sep 21.

13.

p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.

Rizos H, Scurr LL, Irvine M, Alling NJ, Kefford RF.

Cell Cycle. 2007 Jul 15;6(14):1741-7. Epub 2007 May 10.

PMID:
17630509
14.

An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction.

Macias E, Jin A, Deisenroth C, Bhat K, Mao H, Lindström MS, Zhang Y.

Cancer Cell. 2010 Sep 14;18(3):231-43. doi: 10.1016/j.ccr.2010.08.007.

15.

The ARF tumour suppressor.

Gallagher SJ, Kefford RF, Rizos H.

Int J Biochem Cell Biol. 2006;38(10):1637-41. Epub 2006 Feb 28. Review.

PMID:
16600663
16.

p53: guardian of the genome and policeman of the oncogenes.

Efeyan A, Serrano M.

Cell Cycle. 2007 May 2;6(9):1006-10. Epub 2007 May 28. Review.

PMID:
17457049
17.

CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-suppressor pathway.

Kamrul HM, Wadhwa R, Kaul SC.

Ann N Y Acad Sci. 2007 Apr;1100:312-5.

PMID:
17460193
18.

Cooperative effect of p21Cip1/WAF-1 and 14-3-3sigma on cell cycle arrest and apoptosis induction by p14ARF.

Hemmati PG, Normand G, Gillissen B, Wendt J, Dörken B, Daniel PT.

Oncogene. 2008 Dec 4;27(53):6707-19. doi: 10.1038/onc.2008.193. Epub 2008 Sep 22.

PMID:
18806827
19.

Activation of p53 by oncogenes.

Lowe SW.

Endocr Relat Cancer. 1999 Mar;6(1):45-8. Review.

20.

Mdm2 regulates p53 independently of p19(ARF) in homeostatic tissues.

O'Leary KA, Mendrysa SM, Vaccaro A, Perry ME.

Mol Cell Biol. 2004 Jan;24(1):186-91.

Supplemental Content

Support Center